Skip to main content
. 2006 Sep 19;6:8. doi: 10.1186/1471-5945-6-8

Table 3.

Prospective SPC results at week 12

Study IMP 24011[15] Treatment Group Safe Psoriasis Control (SPC)*
Total study group Placebo (n = 165) 12 (7.3 %)
Efalizumab 1.0 mg/kg/wk (n = 329) 113 (34.3 %)
High need group Placebo (n = 117) 4 (3.4 %)
Efalizumab 1.0 mg/kg/wk (n = 221) 73 (33.0 %)

* SPC is defined by PASI <= 8 and DLQI <= 6 and No SAEs and No Severe AEs related to Study Drug and not withdrawn